CD36 and acute myeloid leukemia: In a recent article published in this journal, Aasebø and colleagues reported [1] increased levels of various proteins, including CD36, in acute myeloid leukemia (AML) cells at relapse, when compared with the time of first presentation, and suggest targeting these proteins for direct therapeutic strategies to alleviate chemoresistance in relapsed AML.